摘要
目的比较硝苯地平控释片联合美托洛尔缓释片和厄贝沙坦片联合美托洛尔缓释片对轻中度原发性高血压患者血压变异性(BPV)和肌酸激酶(CK)的影响。方法①入选2017年6月-2018年5月门诊和住院年龄在18~65岁且静息心率≥80次·min-1的初诊为轻中度原发性高血压患者52例为高血压组,选择同期体检的正常人60例为正常血压组,比较两组一般资料的差异;②将52例高血压患者随机分为两组:硝苯地平组(27例,硝苯地平控释片联合美托洛尔缓释片)及厄贝沙坦组(25例,厄贝沙坦片联合美托洛尔缓释片),比较两组治疗前及治疗12周后常规生化和部分24 h动态血压监测指标。结果①高血压组CK、尿酸(UA)与体质量指数(BMI)明显高于正常血压组(P<0.05,P<0.01);②治疗12周后,硝苯地平组及厄贝沙坦组较治疗前平均血压均明显降低(P<0.01),硝苯地平组24 h收缩压标准差(24 h SBPSD)、白昼收缩压标准差(d SBPSD)、夜间收缩压标准差(n SBPSD)较治疗前明显降低(P<0.05);③治疗12周后硝苯地平组及厄贝沙坦组CK、UA等较治疗前均无明显差异(P>0.05),但硝苯地平组CK有下降趋势。结论①硝苯地平组及厄贝沙坦组对轻中度原发性高血压患者降压疗效相当,但硝苯地平组在降低轻中度原发性高血压患者收缩压变异性方面优于厄贝沙坦组;②硝苯地平组与厄贝沙坦组对CK均无明显影响。
Objective To compare the effect of two protocols(metoprolol sustained release tablets combining nifedipine controlled release tablets or metoprolol sustained release tablets combining irbesartan tablets)on blood pressure variability(BPV)and serum creatine kinase(CK)in patients with mild to moderate essential hypertension.Methods①Fifty-two patients newly diagnosed with mild and moderate essential hypertension in the First Hospital of Changsha from June 2017 to May 2018 were selected as the hypertension group.During the same period,60 patients with normal blood pressure in the same hospital were taken as the normal blood pressure group.All the enrolled patients aged between 18 and 65,and their resting heart rate was more than 80 beats per minute.We compared the difference in general data in the two groups.②The hypertension group was randomly divided into a nifedipine group(n=27)and an irbesartan group(n=25).Differences in routine biochemical results and partial 24-hour ambulatory blood pressure monitoring indexes before the treatment and after the 12-week treatment were compared.Results①CK,uric acid(UA)and body mass index(BMI)in the hypertension group were significantly higher than those in normal blood pressure group(P<0.05,P<0.01).②Both blood pressure in the nifedipine group and the irbesartan group decreased significantly after 12 weeks of treatment(P<0.01).In the nifedipine group,the 24 hour systolic blood pressure standard deviation,daytime systolic blood pressure standard deviation and nighttime systolic blood pressure standard deviation were significantly lower than those before the treatment(P<0.05).③After the 12 week treatment,CK,UA and other indicators in the Nifedipine group or in irbesartan group were not significantly different from those before the treatment(P>0.05),but CK in the Nifedipine group tended to decrease.Conclusion①Irbesartan tablets combining metoprolol sustained release tablets shown better the effect on reducing BPV than nifedipine controlled-release tablets combining metopro
作者
谢飘
高天宇
魏亚运
傅广
XIE Piao;GAO Tian-yu;WEI Ya-yun;FU Guang(The First Hospital of Changsha,Changsha Hospital Affiliated to University of South China,Changsha 410005;The Fourth Hospital of Changsha,Changsha 410005)
出处
《中南药学》
CAS
2019年第11期1953-1957,共5页
Central South Pharmacy
基金
湖南省卫生计生委科研基金(No.132015-148)
关键词
联合降压
高血压
血压变异性
肌酸激酶
厄贝沙坦
硝苯地平
美托洛尔
combination therapy forhypertension
hypertension
blood pressure variability
ceatine kinase
irbesartan
nifedipine
metoprolol
